P/B
13,1
Liminatus Pharma
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
Liminatus Pharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing cancer therapies and treatments. The GCC Vaccine of the company is in Phase II of clinical trials designed for immune behavior towards colorectal, pancreatic, gastric, and esophageal cancers that express Guanylyl Cyclase C.
$3.9M
Market Cap • 10/23/2026
2025
(1 year ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
—
P/EBITDA
—
P/OCF
—
P/FCF
—
P/E
—
BVPS
0,2
EPS
—
Market Cap
Market Cap
3,9M
EV
2,4M
EV/Revenue
0
EV/EBITDA
-0,6
EV/EBIT
-0,6
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-143,4%
Total Yield
-143,4%
Payout
0%
Retained Earnings
-41,4M
Profitability
Gross Margin
—
EBITDA Margin
—
EBIT Margin
—
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
0%
Capex/Revenue
0%
Capex/D&A
0%
Capex/OCF
0%
SBC/OCF
—
% PPE
0,3%
% Goodwill
0%
ROE
—
ROIC
—
Leverage
N.D./EBITDA
0,4
Debt/Equity
0%
Current Ratio
1,1
Quick Ratio
1
Interest Coverage
—
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!